396 related articles for article (PubMed ID: 28780375)
1. Adjuvant formulations for virus-like particle (VLP) based vaccines.
Cimica V; Galarza JM
Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
3. Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
Cárdenas-Vargas A; Elizondo-Quiroga D; Gutierrez-Ortega A; Charles-Niño C; Pedroza-Roldán C
Viral Immunol; 2016 Dec; 29(10):557-564. PubMed ID: 27834623
[TBL] [Abstract][Full Text] [Related]
5. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
6. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
7. Zika virus-like particle (VLP) based vaccine.
Boigard H; Alimova A; Martin GR; Katz A; Gottlieb P; Galarza JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005608. PubMed ID: 28481898
[TBL] [Abstract][Full Text] [Related]
8. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
Martins KAO; Cooper CL; Stronsky SM; Norris SLW; Kwilas SA; Steffens JT; Benko JG; van Tongeren SA; Bavari S
EBioMedicine; 2016 Jan; 3():67-78. PubMed ID: 26870818
[TBL] [Abstract][Full Text] [Related]
10. The impact of size on particulate vaccine adjuvants.
Shah RR; O'Hagan DT; Amiji MM; Brito LA
Nanomedicine (Lond); 2014 Dec; 9(17):2671-81. PubMed ID: 25529570
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of virus like particle (VLP) vaccine of foot-and-mouth-disease virus (FMDV) type O adjuvanted with poly I:C or CpG in guinea pigs.
Terhuja M; Saravanan P; Tamilselvan RP
Biologicals; 2015 Nov; 43(6):437-43. PubMed ID: 26493006
[TBL] [Abstract][Full Text] [Related]
12. Formulation and stabilization of recombinant protein based virus-like particle vaccines.
Jain NK; Sahni N; Kumru OS; Joshi SB; Volkin DB; Russell Middaugh C
Adv Drug Deliv Rev; 2015 Oct; 93():42-55. PubMed ID: 25451136
[TBL] [Abstract][Full Text] [Related]
13. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
14. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
15. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
16. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
[TBL] [Abstract][Full Text] [Related]
17. Structural Characterization and Formulation Development of a Trivalent Equine Encephalitis Virus-Like Particle Vaccine Candidate.
Toprani VM; Cheng Y; Wahome N; Khasa H; Kueltzo LA; Schwartz RM; Middaugh CR; Joshi SB; Volkin DB
J Pharm Sci; 2018 Oct; 107(10):2544-2558. PubMed ID: 29883665
[TBL] [Abstract][Full Text] [Related]
18. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
19. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
20. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
